The US Senate and the House of Representatives have released the final text of the 2026 National Defense Authorization Act.
Included within the text is the updated Biosecure Act, which would restrict how US pharmaceutical and biotechnology companies do business with Chinese companies that work with the Chinese military.
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
